BNT23002

BNT23002 is a proprietary sublingual thin-film formulation of cladribine developed by BioNxt Solutions for the treatment of myasthenia gravis (MG). This innovative delivery system offers a non-invasive, patient-friendly alternative to traditional oral or injectable therapies. By utilizing sublingual administration, BNT23002 aims to provide rapid absorption and improved convenience, particularly for patients who may have difficulty swallowing tablets. Cladribine is an immunosuppressive agent that works primarily by depleting lymphocytes, thereby modulating the immune response implicated in autoimmune diseases such as myasthenia gravis[1].